MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis

References

• Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:1–22.
   Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. NASH clinical research network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35:873–878.
   PubMed Web of Science ®Google Scholar
• Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol. 2016;2:1–9.
   PubMedGoogle Scholar
• Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68:362–375.
   PubMed Web of Science ®Google Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–190.
   PubMed Web of Science ®Google Scholar
• Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19–22.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Cavey GS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE. 2013 1-10;8:e61551.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Kletzien RF. Mitochondrial target of thiazolidinediones. Diabetes Obesity Metabolism. 2014;16(11):1048–1054.
   PubMed Web of Science ®Google Scholar
• Herzig S, Raemy E, Montessuit S, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;337:93–96.
   PubMed Web of Science ®Google Scholar
• Yang C, Ko B, Hensley CT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014;56:414–424.
   PubMed Web of Science ®Google Scholar
• McCommis KS, Finck BN. Mitochondrial pyruvate transport: a historical perspective and future research directions. Biochem J. 2015;466:443–454.
   PubMed Web of Science ®Google Scholar
• Bender T, Martinou JC. The mitochondrial pyruvate carrier in health and disease: to carry or not to carry? Biochim Biophys Acta. 2016;1863:2436–2442.
   PubMed Web of Science ®Google Scholar
• Walheim E, Wiśniewski JR, Jastroch M. Respiromics – an integrative analysis linking mitochondrial bioenergetics to molecular signatures. Mol Metab. 2018;31052-9(17):S2212–8778.
   Google Scholar
• Rauckhorst AJ, Gray LR, Sheldon RD, et al. The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity. Mol Metab. 2017;6:1468–1479.
   PubMed Web of Science ®Google Scholar
• McCommis KS, Hodges WT, Brunt EM, et al. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017;65:1543–1556.
   PubMed Web of Science ®Google Scholar
• Divakaruni AS, Wiley SE, Rogers GW, et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. PNAS. 2013;110:5422–5427.
   PubMed Web of Science ®Google Scholar
• Colca JR, Kletzien RF. What has prevented the expansion of the insulin sensitizers? Exp Opin Invest Drugs. 2016;15:205–210.
   Google Scholar
• Colca JR, Tanis SP, McDonald WG, et al. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Exp Opin Invest Drugs. 2013;23:1–7.
   PubMed Web of Science ®Google Scholar
• Chen Z, Vigueira PA, Chambers, et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor-sparing thiazolidinedione. J Biol Chem. 2012;287:23537–23548.
   PubMed Web of Science ®Google Scholar
• McCommis K, McDonald W, Colca J, et al. Acute hepatocyte mitochondrial pyruvate carrier-dependent and -independent effects of MSDC-0602 on liver insulin sensitivity and NASH endpoints in mice. Hepatology. 2017;66:1070A.
   Web of Science ®Google Scholar
• Colca JR. The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin Drug Discov. 2015;10:1259–1270.
   PubMed Web of Science ®Google Scholar
• Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93:352–359.
   PubMed Web of Science ®Google Scholar
• Fukunaga T, Zou W, Rohatgi N, et al. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. 2014;30:481–488.
   Web of Science ®Google Scholar
• Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y). 2014;10:219–227.
   PubMedGoogle Scholar
• Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology. 2017 Dec;9. [Epub ahead of print]. DOI:10.1002/hep.29721
   Google Scholar
• Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62:S65–S75.
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27:22–41.
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, McCommis KS, et al. Treating fatty liver disease by modulating mitochondrial pyruvate metabolism. Hepatol Commun. 2017;1:193–197.
   PubMed Web of Science ®Google Scholar
• Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–315.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Paschetta E, et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633–640.
   PubMed Web of Science ®Google Scholar
• Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17:pii: E1575.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42.
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221–225.
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez I, Santoro N, Chen Y, et al. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest. 2016;126:859–864.
   PubMed Web of Science ®Google Scholar
• Gaggini M, Carli F, Rosso C, et al. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatol. 2018;67:145–158.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castano GO, Scian R, et al. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Am.J Clin Nutr. 2016;103:422–434.
   PubMed Web of Science ®Google Scholar